What You Ought to Know:
– Cohere Well being, a acknowledged chief in medical intelligence and prior authorization automation, introduced that Humana Inc. (NYSE: HUM) will develop its use of Cohere’s prior authorization platform for diagnostic imaging and sleep companies.
– In January 2021, Cohere and Humana started a pilot program in 12 states to enhance the prior authorization course of for musculoskeletal (MSK) companies.
Transformative Prior Authorization Options: Cohere’s Nationwide Impression on Healthcare Entry and Supplier Satisfaction
This system successfully decreased turnaround occasions for prior authorization approvals, boosted supplier satisfaction, and improved care supply for MSK companies. This success led to enlargement throughout all 50 states in 2022. In January 2023, Cohere’s options had been rolled out nationwide, encompassing cardiovascular and surgical companies.
Cohere’s prior authorization platform expedites the approval course of for suppliers and sufferers. Its distinctive mixture of real-time analytics and evidence-based medical intelligence reduces denial charges and facilitates faster affected person entry to care.
Yearly, Cohere handles 5.5 million prior authorizations, benefiting over 15 million well being plan members and 420,000 healthcare suppliers nationwide.
“We’re happy Humana will probably be using our diagnostic imaging and sleep options, additional strengthening our strategic and ongoing partnership,” stated Siva Namasivayam, Chief Govt Officer of Cohere Well being. “Our options are rooted within the newest evidenced-based tips from main medical societies and use superior know-how to align affected person companies inside care pathways by upstream moments of affect, finally enabling sooner diagnoses.”